Collection of peripheral blood mononucleated cells for chronic graft-versus-host disease immunology research: safety and effectiveness of leukapheresis in 132 patients

Alain Mina¹*, Lauren Curtis², Kamille West³, Yu Ying Yau³, Edward W. Cowen⁴, Frances Hakim⁵ and Steven Z. Pavletic¹

Abstract

Background Chronic graft-versus-host disease (GVHD) is a major cause of late morbidity and non-relapse mortality in recipients of allogeneic hematopoietic cell transplantation (HCT). Its biology, however, remains poorly understood, making the studies of its biology and immunomodulatory therapies a difficult task. Such research is often hampered by lymphopenia which is common in these patients and precludes studies of critical cellular subsets across the spectrum of severity of disease. This study explores the potential of leukapheresis to safely acquire and efficiently store immune cells for immunology research in chronic GVHD.

Methods This is a cross-sectional study in which 132 consecutively accrued patients undergo optional research leukapheresis and a one-week comprehensive outpatient evaluation. Baseline clinical and laboratory data and efficiency of the procedure were reported.

Results Ninety-four of 132 patients (71%) achieved the goal collection of $2 \times 10^9$ PBMNCs with a mean volume processed of 4.6 L. Only mild decreases in hemoglobin, platelet, lymphocyte and monocytes were observed. All adverse events were mild (grade 1) and had resolved by the time of discharge from the apheresis unit.

Conclusion This study demonstrates feasibility, safety, and efficiency of research leukapheresis in a frail patient population. Results presented promote leukapheresis as a standard research practice option in studies of chronic GVHD in humans which may expedite advances in our understanding of this complex multisystem disease.

Keywords Apheresis, Peripheral blood mononuclear cells, Chronic graft-versus-host-disease, Transplantation
Background
Chronic GVHD is a major source of late morbidity and non-relapse mortality in patients after allogeneic hematopoietic cell transplantation for hematologic malignancies or other life threatening bone marrow diseases (allo-HCT) [1, 2]. Despite advances in transplantation practices, it continues to affect 30–50% of long-term transplant survivors [3]. The intricacies of chronic GVHD biology remain a challenge and it is not clear yet if a common pathway that would explain the entirety of its manifestations exists. Despite increasing knowledge of immunological factors that contribute to its pathophysiology [4–7], a clearer understanding of chronic GVHD will facilitate diagnosis and optimize immunomodulatory therapies and enhance clinical outcomes [5, 8, 9].

Chronic GVHD shares features with numerous autoimmune disorders, including autoantibody formation, chronic inflammatory mechanisms and systemic sclerotic manifestations, but animal models have not fully replicated human chronic GVHD and there is the prominent need for human based studies [7, 10]. Improved understanding of chronic GVHD could hinge on in depth characterization of cellular and molecular mechanisms of chronic GVHD in allo-HSCT patients. Banking of peripheral blood mononucleated cells (MNC) and sera for research has been an important step in such studies [11]. However, conventional peripheral blood draws often yield insufficient MNC for large scale immunological characterization or functional studies. Furthermore, chronic GVHD patients are frequently lymphopenic, due to immunosuppressive therapy or to the disease process itself [12, 13]. Such lymphopenia constrains studies of rare subsets of T cells or B cells, whose quantitative or functional deficits may crucially contribute to chronic GVHD [14–16]. Leukapheresis has been utilized as an alternative to blood draws, providing lymphocytes that can be either studied immediately or stored for future use in clinical therapy or research setting [17].

As part of our efforts to better understand and treat this complex disease, we explored the potential of leukapheresis to safely acquire and efficiently store immune cells for immunology research in chronic GVHD. We describe here our experience in collecting large quantities of PMNCs from 132 chronic GVHD patients at the National Institutes of Health (NIH) Clinical Center by steady-state peripheral blood leukapheresis, detailing the feasibility, clinical safety, and efficiency of this procedure in this frail patient population.

Methods
Consecutive patients (N=328) were enrolled between October 2004 and March 2014 on the National Cancer Institute protocol, Natural History of Chronic GVHD (NCT00092235), a cross-sectional study in which patients undergo a one-week comprehensive outpatient evaluation. Study received approval from the National Cancer Institute institutional of review board (IRB) and patients provided written consents to undergo leukapheresis for research purposes.

Of these, 132 patients underwent optional research leukapheresis. 47 (24%) declined participation, 39 (20%) had inadequate venous access, 29 (15%) were not candidates due to age (<18 years old), 11 (5%) had acute medical issues that precluded leukapheresis (i.e., pneumonia, positive blood cultures, orthostatic hypotension, new arrhythmia) and 70 (36%) did not undergo leukapheresis because of scheduling conflicts (Table 1). An absolute lymphocyte count (ALC) cutoff of 1.0 K/µL is required at the Department of Transfusion Medicine (DTM) at the NIH to proceed with apheresis as internal data, from healthy donors, has shown low apheresis yield when ALC<1.0 K/µL.

Goal yield was set at 2×10^9 MNC. Goal was chosen based on the expected MNC yield after a 2 L apheresis procedure from prior NIH department of transfusion medicine (DTM) experience with healthy volunteers. Unlike stem cell transplant (SCT) and Chimeric Antigen Receptor (CAR) T cell collections, a set minimum therapeutic cell target was not required.

Devices used for MNC collection were Baxter CS3000 (62 patients, 47%), Haemotronics MCS-P (18 patients, 14%) and COBE SPECTRA (52 patients, 39%). No granulocyte colony stimulating factors (G-CSF) or other stimuliants were administered to the patients. Median whole

| Table 1 Patient Characteristics | n (%) or Median |
|---------------------------------|----------------|
| **Characteristics**             |                |
| Number of eligible patients     | 328            |
| Leukapheresis                   | 132*           |
| No Leukapheresis                | 196 (100)      |
| Lack of consent                 | 47 (24)        |
| Inadequate venous access        | 39 (20)        |
| Pediatric (< 18)                | 29 (15)        |
| Acute medical illness           | 11 (5)         |
| Other (scheduling)              | 70 (36)        |
| Median Age                      | 49.7           |
| (range 18.2–67.7)               |                |
| Gender                          |                |
|  Male                           | 80 (61)        |
| Female                          | 52 (39)        |
| Median Karnofsky performance status | 80 (range 40–100) |
| Chronic GVHD                    |                |
| Severe                          | 82 (62)        |
| Moderate                        | 46 (35)        |
| Mild                            | 4 (3)          |
| Mean number of organs involved  | 4.92           |
| Mean lines of prior systemic treatment | 3.4 |

*gender, performance status and chronic GVHD percentages correspond to patients who underwent leukapheresis (n= 132)
blood flow rate (WBFR) was 60 ml/min (range 35–85 ml/min) and median product volume was 147 ml (range 59–450 ml) (Table 2). Median whole blood/anticoagulant (ACDA) ratio was 12:1, based on plasma requests. Common Terminology Criteria for Adverse Events (CTCAE) were graded based on review of medical records, using version 4.03 (published June 14, 2010). Leukapheresis was done on the last day of the patients’ one week visit.

Results

The median age of patients undergoing leukapheresis was 49.7 years (range: 18.2–67.7). The majority of patients had NIH chronic GVHD global scores that were moderate (46 patients, 35%) or severe (82 patients, 62%). Median Karnofsky performance status was 80 (range 40–100), the mean number of organs involved was 4.9 and the mean number of previous systemic treatments was 3.4 (Table 1). 51 (38%) patients had superficial/dermal sclerosis with a mean body surface area (BSA) affected of 16.8%. 52 patients (40%) had evidence of deep sclerosis with a mean BSA affected of 30.7%. 48 patients (37%) had an absolute pre-leukapheresis lymphocyte count < 1.0 K/µL. 108 (82%) patients underwent 2 arm continuous flow apheresis while 24 patients (18%) underwent one arm intermittent flow apheresis (Table 2). Nine patients (7%) underwent leukapheresis via central venous catheter while the rest via peripheral access (hand, forearm, or antecubital vein).

Ninety-four of 132 patients (71%) achieved the goal collection of $2 \times 10^9$ PBMNCs with a mean volume processed of 4.6 L. Median total run time was 88 min. Pre-leukapheresis Hb, pre-platelet, pre-absolute lymphocytes, pre-absolute monocytes and pre-absolute MNC mean blood counts were 12.4 g/dL, 257.1 K/µL, 1.7 K/µL, 0.70 K/µL and 2.4 K/µL, respectively (Fig. 1). Collection efficiency was calculated using the following equation:

$$CE, \% = \left\{\frac{100\% \times [cell \ content \ in \ product/((average \ pre \ and \ post-apheresis \ blood \ cell \ concentration) \times (volume \ of \ blood \ processed)])}{100}\right\}$$

Mean cell yield and efficiencies were as follows: lymphocytes: $3.74 \times 10^9$, 66.5%; monocytes: $1.07 \times 10^9$, 51.12%; granulocytes: $0.78 \times 10^9$, 4.54%; platelets: $1.93 \times 10^{11}$, 22.24% (Table 3).

Using a previous dataset of 6578 volunteers that underwent apheresis with the same devices at the NIH, as a control cohort, efficiencies were quite comparable to those of our dataset with mean efficiencies being as follows: lymphocytes: 70.9%, monocytes: 30.6%, granulocytes: 6.1% and platelets: 27.6% (See Table A in Supplemental Materials).
As expected, only mild decreases in peripheral cell counts were observed (median change 1-hour post-leu-
kkepheresis): Hgb: -7.9% (p<0.0001); platelets: -21.8% (p<0.0001); WBC: -6.6% (p<0.0001) absolute lympho-
cyte count (ALC): -28.5% (p<0.0001); absolute monocyte count: -28.0% (p<0.0001); MNC: -28.2% (p<0.0001 - Fig.
2). We plotted the pre-apheresis ALC counts against the total lymphocyte yield per liter of blood processed (Fig. 3). An equation that characterizes the line that best fits the different data points can be used to prospectively guide the number of liters processed for different lymphocyte collections (Fig. 3). The pre-apheresis ALC counts could also be plotted against post-apheresis product lymphocyte yield to prospectively predict the individual efficiency of each procedure (Fig. 4). Similarly, the MNC yield could be calculated using each patient's pre-
apheresis ALC counts (Fig. 5).

All adverse events were mild (grade 1) and had resolved by the time of discharge from the apheresis unit: 1 patient had hypotension, 10 had oral dysesthesia, 6 had paresthesia, 1 had anxiety, 2 had localized bleeding and 1 had nausea (Table 4). There was no grade ≥2 adverse events recorded.

Discussion
Advances in reduced intensity conditioning regimens and in more effective antimicrobials have significantly reduced early post-transplant-related morbidity and mortality after allo-HCT. Nevertheless, late post-transplant morbidity and mortality, largely due to chronic GVHD, remains a challenge [18] The pathophysiology of chronic GVHD is complex and a better understanding of it is a must to achieving progress in its management.

Steady-state peripheral blood leukapheresis, or the collection of peripheral blood MNCs for extracorpo-
real photopheresis (ECP) have been used for therapeutic purposes in chronic GVHD [19–22]. Similarly, lymphapheresis is the first step of the manufacturing process of chimeric antigen receptor (CAR) T cells and has been a safe and reliable procedure for the collection of CD3+ lymphocytes from patients after allogeneic HCT [23, 24]. These procedures require a sufficient number of cells for therapeutic processing which could be a major challenge in chronic GVHD where patients are often frail or lymphopenic. Routine use of leukapheresis to acquire larger MNC numbers solely for research purposes in chronic GVHD has not been done due to concerns of logistics, feasibility and patient safety. This current study provides the evidence for the use of leukapheresis as a safe and powerful research tool for advancing knowledge.
about chronic GVHD and provides benchmarks for developing novel therapeutic interventions such as regulatory T cells infusion for GVHD [25] or CAR T cell therapy [26, 27].

One hundred thirty-two (40%) of the chronic GVHD patients in this study underwent research leukapheresis. Results show that independently of disease severity, extent of sclerotic disease, age or blood cell counts,
steady-state PBMC leukapheresis is an overall safe, well-tolerated and effective method for large scale PBMC collection. 71% achieved the goal collection of $2 \times 10^9$ PBMCs, despite our GVHD population that was enriched for moderate/severe disease (97%), including many with deep sclerosis (40%). Notably, 48 patients (37%) were lymphopenic and had a pre-leukapheresis ALC $< 1.0$ K/$\mu$L and would be likely very difficult to study for immunological assays from conventional (20–50 ml) or large volume (250 ml) research blood draws. No patients experienced grade $\geq 2$ adverse events from leukapheresis and all adverse events resolved by the time of discharge from the pheresis unit.

This report demonstrates the feasibility and safety of large scale PMNC collection and storage for research purposes and should support such practice in IRB approved chronic GVHD research protocols. As an example (see Figs. 3 and 4), if one’s research needs to use B- and/or T- lymphocytes and/or monocytes, depending on the specific project needs, it might be possible to state an arbitrary minimum lymphocyte/MNC collection target in the apheresis bag, e.g. $300 \times 10^6$, or $500 \times 10^6$, or $1.0 \times 10^9$ per apheresis bag. In this manner, even for the patients/procedures with the lowest pre-apheresis ALC count, a minimum of $600 \times 10^6$ MNCs were collected in the apheresis bag, which should be adequate for usual research assays (Fig. 2). Looking specifically at total apheresis yield and the lower range of MNC yields, 14 of 132 collections (11%) had yields of $< 1.0 \times 10^9$ (1000 $\times 10^6$), only 3 (2.3%) had yields of $< 0.5 \times 10^9$ (500 $\times 10^6$), and only 1 had yields $< 0.3 \times 10^9$ (or 300 $\times 10^6$), depending on what would be considered a minimum threshold for a successful or usable collection. As an example of their use in research, we and our collaborators at the NIH, were able to separate adequate numbers of FACS-selected cell populations for cell cultures and for gene expression studies relating to mechanisms of chronic GVHD [6]. Similarly, the availability of large numbers of lymphocytes using the 2 L leukapheresis permitted collaborators to analyze gene expression in cultures of sorted B cells from chronic GVHD patients; these studies identified a mechanistic link between NOTCH2 activation and robust B cell activation in chronic GVHD [28]. On the other hand, these yields might be suboptimal in the clinical setting, i.e., for therapeutic purposes. For example, CAR T cell protocols usually specify a much higher minimum number of CD3+ cells in the apheresis bag (e.g. minimum 1000 $\times 10^6$ or 1.0 $\times 10^9$, in order to have at least 2 aliquots of 300–500 $\times 10^6$ CD3+ per aliquot for culture).

Patients with chronic GVHD often have decreased peripheral blood cell counts such as anemia, thrombocytopenia, neutropenia, and particularly lymphopenia,

Table 4  Adverse events with leukapheresis

| Adverse event (Grade 1) | n (%) |
|------------------------|------|
| Oral dysesthesia       | 10 (6) |
| Paresthesia            | 6 (5) |
| Localized bleeding     | 2 (2) |
| Anxiety                | 1 (1) |
| Nausea                 | 1 (1) |
| Hypotension            | 1 (1) |
| Total                  | 21 (16) |

Fig. 5  Apheresis Mononuclear Cell (MNC) Yield versus Patient pre-apheresis ALC counts. Yield can be estimated by the following equation: Product MNC Yield $(10^9) = 0.0788 + 2.38 \times \text{PreALC}$
due to systemic immunosuppressive treatments or the chronic process of GVHD itself. Only mild decreases were observed in peripheral counts in this study after research leukapheresis, and no patients required blood product transfusion, colony-stimulating factors or prophylactic antibiotics. However, in person follow-up after the procedure was limited as leukapheresis was performed on the last day of their outpatient week and patients returned home soon afterwards. All patients received a follow-up phone call by a study practitioner one week after returning home, so it is possible that late onset or more durable adverse events were not adequately captured. Another limitation of our study could be the fact that our patients’ procedures were performed between 2005 and 2014 and since then, both CS300 and Spectra instruments have been retired. Newer devices such as Amicus and Optia exist. Experience with healthy volunteers in our clinic show overall lower platelet yield with Amicus and Optia. As for the healthy volunteers cohort, monocyte collection efficiency was lower using the CS-3000 than for any of the other devices (see Table A, Supplemental Materials).

Advancing efficacy and developing personalized approaches to chronic GVHD therapy remains a major unmet need to improve long term outcomes of patients undergoing allogeneic hematopoietic cell transplantation [29]. Despite major progress in understanding the biology of chronic GVHD, further progress is needed. A better understanding of clinical – biological correlations is needed. Concerns about logistics, feasibility, and safety have been a major barrier to conducting research-directed leukapheresis to reliably obtain large numbers of PBMCNs during chronic GVHD clinical studies. Since about one third of chronic GVHD patients present with substantial lymphopenia many patients, presumably those with more severe disease [12], become excluded from immunology research studies using conventional peripheral blood draw techniques.

This study conclusively demonstrates the feasibility and safety of large scale PMNC collection and storage for research purposes and should support such practice in IRB approved chronic GVHD research protocols.

Conclusion

In conclusion, steady-state PBMC leukapheresis is an overall safe and well-tolerated procedure in patients severely affected by chronic GVHD. Wider utilization of this approach in chronic GVHD clinical protocols should accelerate immunology research into the pathogenesis of the disease. Furthermore, this information will be useful to other research teams, grantees and funding agencies who are considering use of leukapheresis to study rare cell populations or collect PBMCs for therapeutic purposes in patients with advanced chronic GVHD. Leukapheresis should become a tool to achieve more robust research and long-awaited breakthroughs in chronic GVHD.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12967-022-03708-w.

Supplementary Material 1

Supplementary Material 2

Acknowledgements

The authors would like to thank all patients and their families for participating in the NIH cGVHD natural history study. This work was supported by the Intramural Research Program of the National Institutes of Health, Center for Cancer Research, National Cancer Institute. The views expressed in this work do not represent the official views of the National Institutes of Health or the United States Government.

Authors’ contributions

In order of authorship, AM interpreted the patient data and analyzed the outcomes of leukapheresis. He was also a major contributor in writing the manuscript. LC helped with the study design and analyzed and interpreted the patient data. KW and YYY helped with data interpretation, analysis and figure design. EC helped with data interpretation and contributed to the writing of the manuscript. FH helped in study conceptualization, design and data analysis. SP designed the study, interpreted the analyzed data and was a major contributor in writing the manuscript.

Funding

This study was funded by the National Institutes of Health, National Cancer Institute, Center for Cancer Research.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests

The authors declare that they have no competing interests.

Received: 21 August 2022 / Accepted: 17 October 2022
Published online: 08 November 2022

References

1. Arai S, Arora M, Wang T, et al. Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015;21:366–74.
2. Zeiser R, Bizzar BR. Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. N Engl J Med. 2017;377:2565–79.
3. Bachier CR, Aggarwal SK, Hennegan K, Milgroom A, Francis K, Dehipawala S, Rotta M. (2021) Epidemiology and Treatment of Chronic Graft-versus-Host Disease Post-Allogeneic Hematopoietic Cell Transplantation: A US Claims Analysis. Transplant Cell Ther 27:504.e1–504.e6.
4. Socié G, Ritz J. Current issues in chronic graft-versus-host disease. Blood 2014;124:374–84.
5. Im A, Hakim FT, Pavletic SZ. Novel targets in the treatment of chronic graft-versus-host disease. Leukemia. 2017;31:543–54.
6. Hakim FT, Memon S, Jin P et al. Upregulation of IFN-inducible and Damage Response Pathways in Chronic Graft-versus-Host Disease. J Immunol. 2016;197:3490–503.
7. Cooke KR, Luznik L, Sarantopoulos S, et al. The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health. Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017;23:211–34.
8. Koreth J, Kim HT, Jones KT, et al. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood. 2016;128:130–7.
9. Saidu NEB, Bonini C, Dickinson A, Grce M, Inngjerdingen M, Koehl U, Toubert A, Kuzmina Z, Gounden V, Curtis L, et al. Clinical significance of autoantibodies in a large cohort of patients with chronic graft-versus-host disease defined by NIH criteria. Am J Hematol. 2015;90:114–9.
10. Boieri M, Shah P, Dressel R, Inngjerdingen M. The Role of Animal Models in the Study of Hematopoietic Stem Cell Transplantation and GvHD: A Historical Overview. Front Immunol. 2016.
11. Yu J, Storer BE, Kushekhar K, et al. Biomarker Panel for Chronic Graft-Versus-Host Disease. J Clin Oncol. 2016;34:2583–90.
12. Grkovic L, Baird K, Steinberg SM, et al. Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity. Leukemia. 2012;26:633–43.
13. Kansal R, Richardson N, Neeli I, et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med. 2019. https://doi.org/10.1126/scitranslmed.aav1648.
14. Poe JC, Jia W, Su H, et al. An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD. Blood. 2017;130:2131–49.
15. Pavletic SZ, Martin PJ, Schultz RR, Lee SJ. The Future of Chronic Graft-Versus-Host Disease: Introduction to the 2020 National Institutes of Health Consensus Development Project Reports. Transpl Cell Ther. 2021;27:448–51.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.